M&A Deal Summary |
|
|---|---|
| Date | 2016-05-19 |
| Target | Boehringer Ingelheim - Interferon Gamma-1b |
| Sector | Life Science |
| Buyer(s) | Horizon Therapeutics |
| Sellers(s) | Boehringer Ingelheim |
| Deal Type | Divestiture |
| Deal Value | 25M EUR |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2005 |
| Sector | Life Science |
| Employees | 2,100 |
| Revenue | 3.2B USD (2021) |
Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Therapeutics was founded in 2005 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 11 |
| Sector (Life Science) | 6 of 11 |
| Type (Divestiture) | 3 of 4 |
| Country (Germany) | 1 of 1 |
| Year (2016) | 1 of 2 |
| Size (of disclosed) | 9 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-11 |
Crealta Pharmaceuticals
Glendale, Wisconsin, United States Crealta is a specialty pharmaceutical company focused on innovative therapeutics designed to improve patient outcomes. The company, which has two marketed medicines KRYSTEXXA and MIGERGOT, was formed to acquire, develop and market specialty medicines with a focus on select physician specialties. |
Buy | $510M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-09-12 |
Raptor Pharmaceuticals
Novato, California, United States Raptor Pharmaceutical Corp. is a bio pharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases. Raptor Pharmaceuticals Corp. was established in 2005 and is headquartered in Novato, California. |
Buy | $800M |
Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 3 |
| Sector (Life Science) | 1 of 2 |
| Type (Divestiture) | 1 of 3 |
| Country (Germany) | 1 of 2 |
| Year (2016) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-06-17 |
Actimis Pharmaceuticals
San Diego, California, United States Actimis is a biopharmaceutical company focused exclusively on the research and development of small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. |
Buy | $515M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-09-13 |
ViraTherapeutics
Innsbruck, Austria ViraTherapeutics GmbH is a biopharmaceutical company developing promising innovative virus-based immunotherapeutics for the treatment of cancer. ViraTherapeutics developes the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)), which is being investigated alone and in combination with other therapies. ViraTherapeutics GmbH was founded in 2013 and is based in Innsbruck, Austria. |
Buy | €210M |
